Association Between Proton Pump Inhibitors and the Risk of Intestinal Behçet Disease.

IF 3.6 2区医学 Q2 RHEUMATOLOGY

Journal of Rheumatology Pub Date : 2024-12-01 DOI:10.3899/jrheum.2024-0442

Keita Murakami, Junya Arai, Sozaburo Ihara, Yoshihiro Hirata, Yumi Tsuchida, Hirofumi Shoda, Mayo Tsuboi, Ken Kurokawa, Nobumi Suzuki, Hiroto Kinoshita, Yoku Hayakawa, Keishi Fujio, Mitsuhiro Fujishiro

{"title":"Association Between Proton Pump Inhibitors and the Risk of Intestinal Behçet Disease.","authors":"Keita Murakami, Junya Arai, Sozaburo Ihara, Yoshihiro Hirata, Yumi Tsuchida, Hirofumi Shoda, Mayo Tsuboi, Ken Kurokawa, Nobumi Suzuki, Hiroto Kinoshita, Yoku Hayakawa, Keishi Fujio, Mitsuhiro Fujishiro","doi":"10.3899/jrheum.2024-0442","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to investigate the association between proton pump inhibitor (PPI) use and the incidence of intestinal Behçet disease (BD) in patients with BD.Methods: A retrospective cohort study was conducted at The University of Tokyo Hospital, including patients with BD diagnosed between April 2005 and November 2023. Cox models and Kaplan-Meier analyses were used to evaluate hazard ratios (HRs) and cumulative incidence of intestinal BD, respectively. Secondary analyses were performed to assess the duration and dose-response relationship of PPI use.Results: Among 194 patients with BD, 25.3% developed intestinal BD during a mean follow-up of 12 years. PPI users had a significantly higher incidence of intestinal BD compared to nonusers (adjusted HR 2.48, 95% CI 1.38-4.47, P = 0.002), with a confirmed duration/dose-dependent relationship. The cumulative incidence of intestinal BD was markedly elevated in PPI users (log-rank P < 0.001). The result was similar to that in the propensity score-matched cohort.Conclusion: This study demonstrates a significant association between PPI use and increased incidence of intestinal BD in patients with BD. Caution in prescribing PPIs for patients with BD is warranted due to the potential risk of severe complications associated with intestinal BD.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"1193-1197"},"PeriodicalIF":3.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3899/jrheum.2024-0442","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to investigate the association between proton pump inhibitor (PPI) use and the incidence of intestinal Behçet disease (BD) in patients with BD.

Methods: A retrospective cohort study was conducted at The University of Tokyo Hospital, including patients with BD diagnosed between April 2005 and November 2023. Cox models and Kaplan-Meier analyses were used to evaluate hazard ratios (HRs) and cumulative incidence of intestinal BD, respectively. Secondary analyses were performed to assess the duration and dose-response relationship of PPI use.

Results: Among 194 patients with BD, 25.3% developed intestinal BD during a mean follow-up of 12 years. PPI users had a significantly higher incidence of intestinal BD compared to nonusers (adjusted HR 2.48, 95% CI 1.38-4.47, P = 0.002), with a confirmed duration/dose-dependent relationship. The cumulative incidence of intestinal BD was markedly elevated in PPI users (log-rank P < 0.001). The result was similar to that in the propensity score-matched cohort.

Conclusion: This study demonstrates a significant association between PPI use and increased incidence of intestinal BD in patients with BD. Caution in prescribing PPIs for patients with BD is warranted due to the potential risk of severe complications associated with intestinal BD.

查看原文本刊更多论文

质子泵抑制剂与肠道白塞氏病风险之间的关系

研究目的本研究旨在探讨质子泵抑制剂（PPI）的使用与白塞氏病患者肠道白塞氏病（BD）发病率之间的关系：东京大学医院开展了一项回顾性队列研究，研究对象包括2005年4月至2023年11月期间确诊的白塞氏病患者。采用 Cox 模型和 Kaplan-Meier 分析法分别评估肠道 BD 的危险比（HRs）和累积发病率。还进行了二次分析，以评估使用 PPI 的持续时间和剂量反应关系：在 194 名 BD 患者中，25.3% 的患者在平均 12 年的随访期间出现了肠道 BD。与不使用PPI的患者相比，使用PPI的患者肠道BD发病率明显更高（调整后HR为2.48，95% CI为1.38-4.47，P = 0.0024），并证实了持续时间/剂量依赖关系。PPI使用者的肠道BD累积发生率明显升高（对数秩P < 0.001）。该结果与倾向评分匹配队列中的结果相似：结论：该研究表明，服用 PPI 与 BD 患者肠道 BD 发病率增加之间存在明显关联。由于肠道 BD 可能导致严重并发症，因此在为 BD 患者开具 PPIs 处方时应谨慎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Rheumatology 医学-风湿病学

CiteScore

6.50

自引率

5.10%

发文量

285

审稿时长

1 months

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman. The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 41 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.